维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Maria I.Toki"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Benign lymph node microenvironment is associated with response to immunotherapy显示文摘Introduction:Benign lymph nodes have been considered the hubs of immune surveillance in cancer patients.The microenvironment of these lymphoid tissues can be immune suppressed,hence allowing for tumor progression.Understanding the spectrum of benign findings in bystander lymph nodes in immune checkpoint blockade therapy could prove to be key to understanding the mechanism and assessing treatment response.Methods:Benign lymph nodes and spleen were evaluated from patients treated with immunotherapy who subsequently received postmortem examination.We used quantitative immunofluorescence(QIF)to assess tumor infiltrating lymphocytes(TIL)and macrophage marker expression and characterized activation status using a novelmultiplexed QIF assay including CD3,GranzymeB,and Ki67.We performedimmunohistochemistry to correlate results of QIF.Results:Benign lymph nodes from non-responders to immunotherapy showed significantly higher expression of cytotoxic markers and proliferation index(Ki67)in T cells compared to responders.Higher expression of PD-L1 in macrophages was also observed.There was no significant difference in CD3+expression,but higher levels of CD8+T cells as well as CD20+B cells were seen in lymph nodes of non-responders.No significant differences were seen between responder and non-responder splenic tissue.Findings were supported by traditional immunostaining methods.Conclusions:While most studies in biomarkers for immunotherapy focus on tumor microenvironment,we show that benign lymph node microenvironment may predict response to immunotherapy.In responding patients,bystander lymph nodes appear to have been mobilized,resulting in reduced cytotoxic T cells.Conversely,patients whose disease progressed on immunotherapy demonstrate higher levels of macrophages that express increased PD-L1,and activated T cells not recruited to the tumor site.	Maria I.Toki Deepika Kumar Fahad S.Ahmed David L.Rimm Mina L.Xu	2020	Precision Clinical Medicine2020，3，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费